InspireMD (NSPR) News
NASDAQ: NSPRHealth CareMedical/Dental InstrumentsUSD
0.54-0.0805 (-12.97%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
NSPR news summary
We found 11 recent headlines mentioning InspireMD (NSPR): 4 in the past week and 11 in the past 30 days, most often from GlobeNewswire, Nasdaq. NSPR is making an outsized move today, down 12.97% at $0.54, which often coincides with company-specific news. Check the latest headlines below for the likely catalyst. The most recent story, "InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", was published by GlobeNewswire on Nov 20, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest InspireMD headlines
- InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)MIAMI, Nov. 20, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today…GlobeNewswire
- InspireMD Announces First U.S. Commercial TCAR Procedures Using the FDA-Approved CGuard® Prime TransCarotid Stent System- First commercial cases mark return of the CGuard Prime platform to the U.S. market -GlobeNewswire
- InspireMD to Host KOL Webinar on Carotid Artery Disease Management and the Clinical Benefits of InspireMD’s CGuard Prime Carotid Stent PlatformParticipating KOLs include six leading physician experts representing vascular surgery, interventional cardiology, vascular medicine, and neurosurgeryGlobeNewswire
- InspireMD, Inc. Announces Pricing of $37.5 Million Public OfferingOn November 13, 2026, InspireMD, Inc. entered into an underwriting agreement with Lake Street Capital Markets, LLC, as representative of the several underwriters, relating to the issuance and sale in…Nasdaq
- InspireMD Announces Pricing of $37.5 Million Public OfferingMIAMI, Nov. 13, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) ("InspireMD" or the "Company"), developer of the CGuard ® Prime carotid stent system for the prevention of stroke, today…GlobeNewswire
- InspireMD (NSPR) Q3 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The MoNasdaq
- InspireMD Wins FDA Approval For CGuard Prime In Transcarotid Artery Revascularization(RTTNews) - Thursday, InspireMD, Inc. (NSPR) announced that the U.S. Food and Drug Administration (FDA) approved its CGuard Prime TransCarotid Stent System for transcarotid artery revascularization…NasdaqNSPR, BRK.A
- InspireMD Announces Proposed Public OfferingMIAMI, Nov. 12, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard ® Prime carotid stent system for the prevention of stroke, today…GlobeNewswire
- InspireMD Reports Third Quarter 2026 Financial Results- Received FDA approval of CGuard ® Prime for Transcarotid Arterial Revascularization (TCAR) procedures, expected to approximately double the U.S. addressable market -GlobeNewswire
- InspireMD Announces FDA Approval of the CGuard® Prime TransCarotid Stent System for Transcarotid Artery Revascularization (TCAR) Procedures- Approval doubles the CGuard Prime platform’s total addressable market in the U.S. with additional access to over 35,000 TCAR procedures annually –GlobeNewswire
- InspireMD Announces Updated Timing for Third Quarter 2026 Financial ResultsMIAMI, Nov. 11, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard ® Prime carotid stent system for the prevention of stroke, today announced that it has rescheduled its…GlobeNewswire